Codexis Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Codexis stock.
View analyst ratings for Codexis or view top-rated stocks.

Wall Street analysts have given Codexis a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Codexis wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Codexis is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Codexis.

Codexis, Inc. (NASDAQ:CDXS) posted its quarterly earnings results on Thursday, May, 6th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.20) by $0.06. The biotechnology company had revenue of $18 million for the quarter, compared to analyst estimates of $14.85 million. Codexis had a negative net margin of 35.11% and a negative trailing twelve-month return on equity of 19.58%. The firm's quarterly revenue was up 23.3% compared to the same quarter last year.
View Codexis' earnings history.

Codexis' stock was trading at $10.12 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDXS stock has increased by 112.8% and is now trading at $21.54.
View which stocks have been most impacted by COVID-19.

Codexis issued an update on its FY 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share guidance of - for the period. The company issued revenue guidance of $82 million-$85 million, compared to the consensus revenue estimate of $83.27 million.

5 equities research analysts have issued twelve-month price objectives for Codexis' shares. Their forecasts range from $16.00 to $32.00. On average, they anticipate Codexis' stock price to reach $26.60 in the next year. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Codexis or view top-rated stocks among Wall Street analysts.

25 employees have rated Codexis CEO John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among Codexis' employees.

Some companies that are related to Codexis include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of CDXS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), (CGC), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

Codexis trades on the NASDAQ under the ticker symbol "CDXS."

Codexis' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (9.74%), Baillie Gifford & Co. (9.20%), BlackRock Inc. (7.95%), Gilder Gagnon Howe & Co. LLC (3.81%), Telemark Asset Management LLC (3.81%) and William Blair Investment Management LLC (3.65%). Company insiders that own Codexis stock include Bernard J Kelley, Byron L Dorgan, Dennis P Wolf, John J Nicols, Patrick Y Yang and Thomas R Baruch.
View institutional ownership trends for Codexis.

CDXS stock was sold by a variety of institutional investors in the last quarter, including Telemark Asset Management LLC, Janus Henderson Group PLC, Millennium Management LLC, Goldman Sachs Group Inc., First Light Asset Management LLC, Union Square Park Capital Management LLC, Assenagon Asset Management S.A., and State of New Jersey Common Pension Fund D. Company insiders that have sold Codexis company stock in the last year include Bernard J Kelley, Dennis P Wolf, John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis or view top insider-selling stocks.

CDXS stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, BlackRock Inc., Pier Capital LLC, Nuveen Asset Management LLC, Morgan Stanley, William Blair Investment Management LLC, Dimensional Fund Advisors LP, and Castleark Management LLC. Company insiders that have bought Codexis stock in the last two years include John J Nicols, and Patrick Y Yang.
View insider buying and selling activity for Codexis or or view top insider-buying stocks.

Shares of CDXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CDXS stock can currently be purchased for approximately $21.54.

Codexis has a market capitalization of $1.39 billion and generates $69.06 million in revenue each year. The biotechnology company earns $-24,010,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

Codexis employs 181 workers across the globe.

The official website for Codexis is www.codexis.com.

Codexis is headquartered at 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063.

Codexis' mailing address is 200 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The biotechnology company can be reached via phone at 650-421-8100 or via email at [email protected]